EBD Group is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

7:00am - 6:00pm 660 mins
Registration Open – Hilton Union Square

Plaza A, Lobby Level

Please note: The registration desk will be open all day.

7:00am - 8:00am 60 mins
Continental Breakfast – Hilton Union Square

Grand Ballroom

8:00am - 9:00am 60 mins
The metabolic syndrome epidemic – Hilton Union Square
  • Moderator Philip Kenner - Principal, ClearView Healthcare Partners
  • Panelist Brian T. Bloomquist - Senior Director, Diabetes External Innovation, Eli Lilly and Company
  • Panelist Deborah Dunsire - CEO and President, XTuit
  • Panelist Michael Graffeo - Senior Partner, Graffeo & Associates
  • Panelist Tomas Landh - Innovation Sourcing VP, Senior Principal Scientist, Innovation Sourcing, Novo Nordisk
  • Panelist Harith Rajagopalan - Co-Founder and CEO, Fractyl Laboratories
  • Panelist Ken Song - President and CEO, Metacrine Inc.

Yosemite B

Metabolics as a therapeutic area is evolving through expansion into adjacent diseases such as obesity, NASH and hypertension. This broadening of focus is a means for continued innovation and return on investment. As companies begin to understand the underlying links between type 2 diabetes and its co-morbidities, there is a greater investment in expanding a traditionally narrow-focused portfolio. Recently, NASH appears to be the most promising indication with many players in development, an increase in deal flow, and a rise in investor interest. However, there are challenges around how to demonstrate clinical and economic value. Join us for an interactive discussion around these topics.

8:00am - 6:00pm 600 mins
One-to-one meetings – Hilton Union Square

Grand Ballroom

Please note: One-to-one meetings will take place all day depending on your partnering schedule.

8:30am - 12:00pm 210 mins
Company Presentations – Hilton Union Square

Yosemite A–C; Franciscan A–D

9:00am - 10:00am 60 mins
Infectious disease in the age of resistance – Hilton Union Square
  • Moderator Bibhash Mukhopadhyay - Principal, New Enterprise Associates
  • Panelist Alan Carr - Senior Analyst, Biotechnology, Needham & Company, LLC
  • Panelist Julia Gregory - Former CEO, Contrafect
  • Panelist Kenneth Hillan - CEO, Achaogen
  • Panelist Gregory G. Mario - CEO, TAXIS Pharmaceuticals, Inc
  • Panelist John Rex - Chief Medical Officer and Director, F2G, Ltd; Expert-in-Residence, Wellcome Trust; Operating Partner, Advent Life Sciences
  • Panelist Chris Stevens - Chief Medical Officer, Arsanis

Yosemite B

Anti-microbial drug development has received renewed enthusiasm from select companies after a drought of new marketing approvals for a decade and a half, spurred by the emergence of anti-microbial resistance (AMR) as a key public health concern highlighted both by the WHO globally and the CDC in the US, as well as renewed interest from biotech companies and investors. The panelists assembled are at the leading edge of anti-microbial drug development and will discuss the tailwinds and headwinds in the space, what it takes to get an anti-bacterial or anti-fungal drug approved, how to create a successful commercially sustainable business and what is exciting in the pipeline.

12:00pm - 1:45pm 105 mins
Lunch Plenary: What it means to be in the era of cures – Hilton Union Square
  • Moderator Alice Valder Curran - Partner, Hogan Lovells
  • Panelist Eric Aguiar - Partner, Aisling Capital LLC
  • Panelist Philippe Lopes-Fernandes - Senior VP, Head of Global Licensing and Business Development, Merck KGaA
  • Panelist Camille Samuels - Partner, Venrock
  • Panelist Pascal Touchon - Senior VP and Global Head, Cell and Gene, Novartis Oncology
  • Panelist Robert E. Ward - Chairman and CEO, Eloxx Pharmaceuticals

Imperial Ballroom

From Sovaldi to CAR-T, and immuno-oncology to gene therapy, the biotechnology industry is shifting the focus of product development from treatments to cures. Still playing catch-up are our public and private markets, whose current mechanisms for coverage, pricing, and liability are designed for maintenance therapy and single-indication treatments. The resulting mismatch between current regulatory schemes and new curative therapies makes even more complex the already difficult and expensive early-stage decisions regarding what product candidates to pursue. Hear how stakeholders are considering these factors and risks as they identify, develop, and commercialize products that are transforming the future of the industry.

1:45pm - 5:30pm 225 mins
Company Presentations – Hilton Union Square

Yosemite A–C; Franciscan A–D

3:30pm - 4:30pm 60 mins
Data as the new rocket fuel for healthcare investing – Hilton Union Square
  • Moderator Steve Dickman - Founder and CEO, CBT Advisors
  • Panelist Ron Alfa - VP, Discovery and Product, Recursion Pharmaceuticals
  • Panelist Gary Kurtzman - Senior VP and Managing Director, Safeguard
  • Panelist Katherine Merton - Head, JLABS NYC, Johnson & Johnson Innovation
  • Panelist Ajit Singh - Managing Director and General Partner, Artiman Ventures

Imperial Ballroom

The last several years have seen an upsurge of investments in companies that are aggregating data and performing analytics instead of (or in addition to) directly helping patients. The allure of AI and machine learning has begun to further energize this space. What do data-focused companies plan next? How do investors think about the space?

4:30pm - 5:30pm 60 mins
Drivers of innovation: Evolving models in rare disease drug development – Hilton Union Square
  • Moderator Daniel Levine - Editor, RARE Daily; Host, RARECast; Principal, Levine Media Group
  • Panelist Brinda Balakrishnan - Group VP, Corporate and Business Development, BioMarin
  • Panelist Sarah Boyce - Senior VP and Chief Business Officer, Ionis Pharmaceuticals, Inc
  • Panelist Neil Kumar - CEO, BridgeBio
  • Speaker Robert Pacifici - Chief Scientific Officer, CHDI

Imperial Ballroom

The growing pressure on drug companies to bring new rare disease therapies quickly and cost-effectively is giving rise to a variety of emerging business models. While there are a number of fully integrated pharmaceutical companies in the space, others are focusing on licensing a platform technology, acting more like an incubator, or driving an array of projects through a collaboration model. What do companies gain or lose through such strategies? How do they accelerate the development of new therapies? How do investors view these models?

Showing of Streams